SAN

80.38

-0.73%↓

SAN

80.38

-0.73%↓

SAN

80.38

-0.73%↓

SAN

80.38

-0.73%↓

SAN

80.38

-0.73%↓

Search

Vetoquinol SA

Fermé

SecteurSoins de santé

86.8 1.52

Résumé

Variation du prix de l'action

24h

Actuel

Min

86.4

Max

86.9

Chiffres clés

By Trading Economics

Revenu

25M

Ventes

258M

P/E

Moyenne du Secteur

16.569

84.243

Rendement du dividende

1.02

Marge bénéficiaire

9.734

Employés

2,497

EBITDA

48M

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.02%

2.28%

Prochains Résultats

27 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1B

Ouverture précédente

85.28

Clôture précédente

86.8

Sentiment de l'Actualité

By Acuity

25%

75%

46 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Vetoquinol SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 févr. 2026, 23:57 UTC

Market Talk

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8 févr. 2026, 23:47 UTC

Market Talk

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8 févr. 2026, 23:43 UTC

Market Talk

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8 févr. 2026, 23:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 févr. 2026, 23:34 UTC

Market Talk

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8 févr. 2026, 23:26 UTC

Market Talk

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8 févr. 2026, 22:55 UTC

Résultats

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8 févr. 2026, 21:43 UTC

Market Talk

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8 févr. 2026, 21:16 UTC

Market Talk

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8 févr. 2026, 21:15 UTC

Market Talk

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7 févr. 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7 févr. 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 févr. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 févr. 2026, 02:46 UTC

Acquisitions, Fusions, Rachats

Big Money, High Anxiety -- Barrons.com

6 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 févr. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6 févr. 2026, 21:40 UTC

Acquisitions, Fusions, Rachats

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 févr. 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 févr. 2026, 21:17 UTC

Résultats

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 févr. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 févr. 2026, 21:14 UTC

Acquisitions, Fusions, Rachats

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 févr. 2026, 21:13 UTC

Résultats

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 févr. 2026, 21:13 UTC

Résultats

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 févr. 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 févr. 2026, 20:34 UTC

Résultats

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Comparaison

Variation de prix

Vetoquinol SA prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

72.6 / 75.1Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

46 / 352Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
help-icon Live chat